Duopharma Biotech Bhd
Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers consumer healthcare products, such as vitamins, minerals, and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as ca… Read more
Duopharma Biotech Bhd (7148) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.040x
Based on the latest financial reports, Duopharma Biotech Bhd (7148) has a cash flow conversion efficiency ratio of 0.040x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (RM30.27 Million) by net assets (RM757.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Duopharma Biotech Bhd - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Duopharma Biotech Bhd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Duopharma Biotech Bhd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Duopharma Biotech Bhd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Grand Fortune Securities Co Ltd
TWO:6026
|
0.045x |
|
Nex Point Public Company Limited
BK:NEX
|
-0.003x |
|
AC Immune Ltd
NASDAQ:ACIU
|
-0.294x |
|
7707
TWO:7707
|
-0.037x |
|
Mokingran Jewellery Group Co., Ltd.
F:0HY
|
N/A |
|
Varia US Properties AG
LSE:0RKW
|
0.001x |
|
Acme United Corporation
NYSE MKT:ACU
|
0.061x |
|
CHC Resources Corp
TW:9930
|
0.081x |
Annual Cash Flow Conversion Efficiency for Duopharma Biotech Bhd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Duopharma Biotech Bhd from 2006 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | RM757.62 Million | RM112.71 Million | 0.149x | +28.40% |
| 2024-12-31 | RM709.15 Million | RM82.16 Million | 0.116x | +54.42% |
| 2023-12-31 | RM687.12 Million | RM51.55 Million | 0.075x | -30.04% |
| 2022-12-31 | RM655.22 Million | RM70.27 Million | 0.107x | +54.89% |
| 2021-12-31 | RM624.00 Million | RM43.20 Million | 0.069x | -37.52% |
| 2020-12-31 | RM643.82 Million | RM71.35 Million | 0.111x | -12.32% |
| 2019-12-31 | RM529.75 Million | RM66.96 Million | 0.126x | -15.94% |
| 2018-12-31 | RM481.04 Million | RM72.33 Million | 0.150x | +28.73% |
| 2017-12-31 | RM479.87 Million | RM56.05 Million | 0.117x | +59.71% |
| 2016-12-31 | RM454.52 Million | RM33.24 Million | 0.073x | +164.65% |
| 2015-12-31 | RM449.72 Million | RM-50.88 Million | -0.113x | -160.89% |
| 2014-12-31 | RM193.63 Million | RM35.97 Million | 0.186x | -14.16% |
| 2013-12-31 | RM182.65 Million | RM39.53 Million | 0.216x | -4.12% |
| 2012-12-31 | RM170.50 Million | RM38.49 Million | 0.226x | +91.65% |
| 2011-12-31 | RM164.44 Million | RM19.37 Million | 0.118x | -53.56% |
| 2010-12-31 | RM157.87 Million | RM40.04 Million | 0.254x | +33.09% |
| 2009-12-31 | RM142.74 Million | RM27.20 Million | 0.191x | -5.97% |
| 2008-12-31 | RM130.55 Million | RM26.46 Million | 0.203x | -7.77% |
| 2007-12-31 | RM114.21 Million | RM25.10 Million | 0.220x | +18.17% |
| 2006-12-31 | RM145.43 Million | RM27.04 Million | 0.186x | -- |